Drug intelligence / Profile preview

GS201

Development stage: Preclinical
Lead developer: Jiangsu Genscend Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GS201 is a monoclonal antibody biosimilar/biobetter of pembrolizumab (Keytruda) being developed by Genscend Biopharmaceutical. It targets programmed cell death protein 1 (PD-1) and is designed to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell-mediated antitumor immune responses. The drug is currently in preclinical and IND-enabling development for the treatment of various oncology indications, with an Investigational New Drug (IND) application projected for the second quarter of 2027.

Other names: pembrolizumab biobetterpembrolizumab biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on GS201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS201.

Explore the full profile